Centralne Biuro Sledcze Policji, 2024)
In addition, decreased femur length, width and thickness of cortical bone, decreased thickness of the tibial growth plate and minimal to mild bone marrow hypocellularity were noted at doses equal to or greater than 14 mg/kg/day (about 3.4 times an oral human dose of 40 mg on a body surface area basis)
Deficiency signs and symptoms include: - Difficulty thinking and remembering - Fatigue - Lack of energy - Persistent headaches - Heart palpitations - Pale skin - Weight loss - Infertility - Numbness and tingling in the hands and feet - Mood changes - A sore tongue and/or mouth ulcers - Low or lack of appetite - Constipation The Benefits: Increased Energy & Stamina Supports red blood cell production to combat fatigue and improve overall energy levels
Most protocols recommend consistent use over several weeks to months
As a result, coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively (Table 1)
Gwyer, D., Wragg, N.M